We are a leading medical device company exclusively focused on the foot and ankle orthopedic market and we are dedicated to improving patient lives. Our innovative orthopedic solutions, procedural approaches and instrumentation cover a wide range of foot and ankle ailments, including fracture fixation, hallux valgus (bunions), hammertoe, progressive collapsing foot deformity (PCFD) or flat foot, and charcot foot. To treat these painful, debilitating or even life-threatening conditions, we provide a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Our broad suite of surgical solutions comprises 72 product systems, including approximately 8,700 SKUs to help fit the specific needs of each patient and procedure. We design each of our products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent and reproducible.

(Note: Paragon 28, Inc. priced its IPO on Oct. 14, 2021, at $16 – the mid-point of its $15-to-$17 price range – on 7.81 million shares, the same number of shares in the prospectus, to raise $124.96 million.)